Standard Monitoring Guidelines for Tigecycline
Tigecycline, an intravenous glycylcycline antibiotic used for complicated infections, requires liver function tests (LFTs) due to risks of elevated transaminases and rare hepatotoxicity. The prescribing information recommends performing LFTs (including ALT, AST, alkaline phosphatase, total bilirubin, and direct bilirubin) prior to treatment initiation, periodically during treatment, and at discontinuation.[1][2]
No fixed interval (e.g., weekly or monthly) is specified; "periodically" is interpreted based on patient risk factors, treatment duration, and clinical judgment. For most patients, this means baseline testing followed by checks every 1-2 weeks or as clinically indicated.[2][3]
When to Test More Frequently
Increase LFT frequency for high-risk patients:
- Those with preexisting liver disease, hepatitis, or alcohol use.
- Prolonged therapy (>14 days), common in hospital settings.
- Symptoms like jaundice, dark urine, nausea, or right upper quadrant pain.
In these cases, test weekly or biweekly, and discontinue if transaminases exceed 5x upper limit of normal (ULN) without other cause.[1][2]
Why This Monitoring Matters
Tigecycline causes asymptomatic ALT/AST elevations in up to 25% of patients, typically mild (2-3x ULN) and reversible post-treatment. Severe cases (>10x ULN) occur in <1%, but hepatic failure has been reported rarely.[1][3] Guidelines from IDSA and FDA emphasize this to catch issues early, especially since tigecycline is often used in critically ill patients with comorbidities.
Comparison to Similar Antibiotics
Unlike vancomycin (daily troughs but less LFT focus) or linezolid (weekly CBC/LFTs), tigecycline's LFT monitoring aligns more with other tetracyclines but is stricter due to its biliary excretion and hepatotoxicity profile.[3]
Clinical Trial Data on Liver Events
In phase 3 trials (n>5,000), 15-26% had ALT increases vs. 8-15% comparators; most resolved without intervention. No clear dose-response, but longer exposure raised risk.[1]
Sources
[1]: Tygacil (tigecycline) Prescribing Information - Pfizer
[2]: FDA Label for Tigecycline
[3]: IDSA Guidelines on Antimicrobial Monitoring